' 
SCIENTIFIC SCORE
Questionable
Based on 2 Researches
6.5
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: 3 Softgels
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%**
Total Carbohydrate
2 g
1%**
Protein
less than 1 g
Reducol Plant sterols/stanols (as esters)††
900 mg
*
Pantethine (Pantesin)
300 mg
*
Top Medical Research Studies
5
Immunoadsorption therapy's limited impact
Effect of immunoadsorption on clinical presentation and immune alterations in COVID-19-induced and/or aggravated ME/CFS.
Protein treatment effects evaluated
We aimed to understand how immunoadsorption therapy, which removes certain proteins from the blood, affects individuals with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) following a COVID-19 infection.
Our study focused on 12 post-COVID patients experiencingME/CFS symptoms, heightened levels of specific autoantibodies, and neurological issues. We found that after receiving immunoadsorption therapy, there was a marked decrease in these troublesome autoantibodies associated with the autonomic nervous system.
Additionally, the therapy led to reduced levels of pro-inflammatory cytokines—substances involved in the body's immune response—which correlated with the presence of spike proteins in some patients. Despite these changes, we noted that, thirty days after therapy, while there were improvements in neuropsychological function and some physical strength, the self-reported symptoms and overall scores on ME/CFS questionnaires did not show significant improvement.
Therefore, while immunoadsorption therapy showed promise in altering certain immune markers, it did not lead to a substantial improvement in the patients' overall experience of ME/CFS.
Our study focused on 12 post-COVID patients experiencingME/CFS symptoms, heightened levels of specific autoantibodies, and neurological issues. We found that after receiving immunoadsorption therapy, there was a marked decrease in these troublesome autoantibodies associated with the autonomic nervous system.
Additionally, the therapy led to reduced levels of pro-inflammatory cytokines—substances involved in the body's immune response—which correlated with the presence of spike proteins in some patients. Despite these changes, we noted that, thirty days after therapy, while there were improvements in neuropsychological function and some physical strength, the self-reported symptoms and overall scores on ME/CFS questionnaires did not show significant improvement.
Therefore, while immunoadsorption therapy showed promise in altering certain immune markers, it did not lead to a substantial improvement in the patients' overall experience of ME/CFS.
Read More
8
Collagen treatment aids chronic fatigue
Polymerized Type I Collagen Downregulates STAT-1 Phosphorylation Through Engagement with LAIR-1 in Circulating Monocytes, Avoiding Long COVID.
Moderate relevance to chronic fatigue
We delved into the effects of polymerized type I collagen (PTIC) on chronic fatigue syndrome, particularly in symptomatic COVID-19 outpatients. Our investigation suggested that PTIC could play a role in reducing hyperinflammation—a common issue tied to prolonged COVID symptoms, including chronic fatigue.
The study presented how when PTIC was administered, it engaged with a receptor known as LAIR-1. This interaction was shown to downregulate a specific inflammatory protein, pSTAT1, particularly in immune cells called M1 macrophages. Notably, patients receiving PTIC exhibited a significant drop in several pro-inflammatory cytokines associated with STAT1.
Furthermore, we observed improvements in various symptoms related to COVID-19, such as better oxygen saturation and reduced instances of dyspnea, chest pain, cough, and chronic fatigue. The downregulation of inflammatory mediators alongside the increase in a different subset of monocytes (Mo2) painted a hopeful picture for those struggling with long-term effects of COVID-19. While the primary focus was on treating COVID-19 symptoms, this treatment could have implications for tackling chronic fatigue syndrome as well.
The study presented how when PTIC was administered, it engaged with a receptor known as LAIR-1. This interaction was shown to downregulate a specific inflammatory protein, pSTAT1, particularly in immune cells called M1 macrophages. Notably, patients receiving PTIC exhibited a significant drop in several pro-inflammatory cytokines associated with STAT1.
Furthermore, we observed improvements in various symptoms related to COVID-19, such as better oxygen saturation and reduced instances of dyspnea, chest pain, cough, and chronic fatigue. The downregulation of inflammatory mediators alongside the increase in a different subset of monocytes (Mo2) painted a hopeful picture for those struggling with long-term effects of COVID-19. While the primary focus was on treating COVID-19 symptoms, this treatment could have implications for tackling chronic fatigue syndrome as well.
Read More
Most Useful Reviews
8.8
Eases CFS symptoms
I’ve been taking this supplement to reduce the frequency of my migraines at my neurologist's suggestion. Surprisingly, within three months, I noticed a marked reduction in my chronic fatigue syndrome symptoms as well. Although it took a year to see the migraine benefits, the unexpected relief from CFS symptoms was truly delightful. The quality of Nature Made products is consistently great, and this one did not let me down. I find that taking these helps me immensely.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 2 Researches
6.5
- All Researches
8
Collagen treatment aids chronic fatigue
Polymerized Type I Collagen Downregulates STAT-1 Phosphorylation Through Engagement with LAIR-1 in Circulating Monocytes, Avoiding Long COVID.
Moderate relevance to chronic fatigue
We delved into the effects of polymerized type I collagen (PTIC) on chronic fatigue syndrome, particularly in symptomatic COVID-19 outpatients. Our investigation suggested that PTIC could play a role in reducing hyperinflammation—a common issue tied to prolonged COVID symptoms, including chronic fatigue.
The study presented how when PTIC was administered, it engaged with a receptor known as LAIR-1. This interaction was shown to downregulate a specific inflammatory protein, pSTAT1, particularly in immune cells called M1 macrophages. Notably, patients receiving PTIC exhibited a significant drop in several pro-inflammatory cytokines associated with STAT1.
Furthermore, we observed improvements in various symptoms related to COVID-19, such as better oxygen saturation and reduced instances of dyspnea, chest pain, cough, and chronic fatigue. The downregulation of inflammatory mediators alongside the increase in a different subset of monocytes (Mo2) painted a hopeful picture for those struggling with long-term effects of COVID-19. While the primary focus was on treating COVID-19 symptoms, this treatment could have implications for tackling chronic fatigue syndrome as well.
The study presented how when PTIC was administered, it engaged with a receptor known as LAIR-1. This interaction was shown to downregulate a specific inflammatory protein, pSTAT1, particularly in immune cells called M1 macrophages. Notably, patients receiving PTIC exhibited a significant drop in several pro-inflammatory cytokines associated with STAT1.
Furthermore, we observed improvements in various symptoms related to COVID-19, such as better oxygen saturation and reduced instances of dyspnea, chest pain, cough, and chronic fatigue. The downregulation of inflammatory mediators alongside the increase in a different subset of monocytes (Mo2) painted a hopeful picture for those struggling with long-term effects of COVID-19. While the primary focus was on treating COVID-19 symptoms, this treatment could have implications for tackling chronic fatigue syndrome as well.
Read More
5
Immunoadsorption therapy's limited impact
Effect of immunoadsorption on clinical presentation and immune alterations in COVID-19-induced and/or aggravated ME/CFS.
Protein treatment effects evaluated
We aimed to understand how immunoadsorption therapy, which removes certain proteins from the blood, affects individuals with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) following a COVID-19 infection.
Our study focused on 12 post-COVID patients experiencingME/CFS symptoms, heightened levels of specific autoantibodies, and neurological issues. We found that after receiving immunoadsorption therapy, there was a marked decrease in these troublesome autoantibodies associated with the autonomic nervous system.
Additionally, the therapy led to reduced levels of pro-inflammatory cytokines—substances involved in the body's immune response—which correlated with the presence of spike proteins in some patients. Despite these changes, we noted that, thirty days after therapy, while there were improvements in neuropsychological function and some physical strength, the self-reported symptoms and overall scores on ME/CFS questionnaires did not show significant improvement.
Therefore, while immunoadsorption therapy showed promise in altering certain immune markers, it did not lead to a substantial improvement in the patients' overall experience of ME/CFS.
Our study focused on 12 post-COVID patients experiencingME/CFS symptoms, heightened levels of specific autoantibodies, and neurological issues. We found that after receiving immunoadsorption therapy, there was a marked decrease in these troublesome autoantibodies associated with the autonomic nervous system.
Additionally, the therapy led to reduced levels of pro-inflammatory cytokines—substances involved in the body's immune response—which correlated with the presence of spike proteins in some patients. Despite these changes, we noted that, thirty days after therapy, while there were improvements in neuropsychological function and some physical strength, the self-reported symptoms and overall scores on ME/CFS questionnaires did not show significant improvement.
Therefore, while immunoadsorption therapy showed promise in altering certain immune markers, it did not lead to a substantial improvement in the patients' overall experience of ME/CFS.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
8.8
Eases CFS symptoms
I’ve been taking this supplement to reduce the frequency of my migraines at my neurologist's suggestion. Surprisingly, within three months, I noticed a marked reduction in my chronic fatigue syndrome symptoms as well. Although it took a year to see the migraine benefits, the unexpected relief from CFS symptoms was truly delightful. The quality of Nature Made products is consistently great, and this one did not let me down. I find that taking these helps me immensely.
Read More
